JAK inhibitors (Rigel Pharmaceuticals)

N/A

Report date: 2025/03/20 16:06:55
NME

Base Information

Drug NameJAK inhibitors (Rigel Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionJanus kinase inhibitors
TargetsJanus kinase
Therapy Area/IndicationsArthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRigel Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsArthritis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A